# CIMERLI

NDC: 70114-441
Generic name: ranibizumab-eqrn
Labeler / Manufacturer: Coherus BioSciences Inc
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAVITREAL
Marketing started: 20221003
Marketing ended: 20270131
FDA application: BLA761165

## Active ingredients

- RANIBIZUMAB: .5 mg/.05mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"70114-441"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=70114-441
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0e23118-1490-a554-e053-2995a90ab90c